Founded 1959 | Website www.hovione.com Number of employees 1,170 Parent organization Hovione Limited | |
 | ||
Key people Guy Villax (CEO)Diane Villax (chairman) Products Pharmaceutical Fine ChemicalsOff-Patent APIsInhalation Services Drug SubstanceDrug ProductParticle EngineeringProprietary Product Licensing Subsidiaries Zhejiang Hisyn Pharmaceutical Co., Ltd., Hovione LLC, Hovione PharmaScience Ltd. Profiles | ||
Hovione rings the closing bell to celebrate the listing of 40 million in bonds
Hovione is a Portuguese company that produces active pharmaceutical ingredients (APIs) and conducts drug product intermediates development and compliant manufacture. It has sites in the United States, Portugal, Ireland and China. The company provides a number of products and services to the pharmaceutical industry including separate or integrated API, pre-formulated compounds, particle engineering, formulation development and manufacturing. It also supports highly potent compounds and proprietary product development and licensing for drug products. It is also present in the inhalation area.
Contents
- Hovione rings the closing bell to celebrate the listing of 40 million in bonds
- History
- Research and development
- Strategy
- References
History
Hovione continues to be a privately held company with 5 plants - in Portugal (1969), Macao (1986), New Jersey (2001), Taizhou in mainland China (2008) and Cork, Ireland (2009) - have a total reactor capacity of 1300 m³ and 1100 people worldwide. Since Hovione started operations in 1959, the company has patented more than 100 innovative chemical processes and produced industrially over 45 different APIs. All Hovione sites have been successfully inspected either by FDA, European Medicines Agency or the PMDA Japanese agency.
Hovione is a major source of semi-synthetic tetracyclines and corticosteroids, and is the largest independent supplier of contrast agents – these three families of compounds make up most of its generic product portfolio. The other half of the business focuses on exclusive projects:
Research and development
Hovione invested an estimated $12.7 million in research and development in 2005, equal to around 15 per cent of sales in 2005. The Portuguese company claimed to be the pharmaceutical producer with the highest R&D investment in Portugal.
Strategy
Hovione was always present in the pharmaceutical industry offering products and services related to the development and manufacture of either a new chemical entity (NCE) for an exclusive contract manufacturing partner or an existing API for an off-patent product. In nowadays it is an integrated solution provider, from process chemistry to particle engineering to formulation, from very small scale to full commercial capacity and from preclinical to market. In the area of technologies, it has capabilities in spray drying (also for potent drugs), spray congealing, fluidized spray drying, aseptic spray drying, jet milling, controlled crystallization, microfluidization. And methodologies Quality by Design, process analytical technology (PAT), britest, lean, scale-up science, modeling.